Business Description
Unicycive Therapeutics Inc
NAICS : 325110
SIC : 2834
ISIN : US90466Y1038
Share Class Description:
UNCY: Ordinary SharesDescription
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 40.08 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -73.4 | |||||
| 3-Year EPS without NRI Growth Rate | -48.2 | |||||
| 3-Year FCF Growth Rate | -63.7 | |||||
| 3-Year Book Growth Rate | 21.5 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.91 | |||||
| 9-Day RSI | 45.52 | |||||
| 14-Day RSI | 51.41 | |||||
| 6-1 Month Momentum % | -16.59 | |||||
| 12-1 Month Momentum % | -8.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.61 | |||||
| Quick Ratio | 3.61 | |||||
| Cash Ratio | 3.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -43.4 | |||||
| Shareholder Yield % | 0.01 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -3928.3 | |||||
| ROE % | -142.79 | |||||
| ROA % | -67.94 | |||||
| ROIC % | -207.89 | |||||
| ROC (Joel Greenblatt) % | -2975.09 | |||||
| ROCE % | -139.02 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 23.7 | |||||
| PB Ratio | 2.29 | |||||
| Price-to-Tangible-Book | 2.29 | |||||
| EV-to-EBIT | -1.78 | |||||
| EV-to-EBITDA | -1.82 | |||||
| EV-to-Revenue | 60.62 | |||||
| EV-to-Forward-Revenue | 1.77 | |||||
| EV-to-FCF | -1.54 | |||||
| Price-to-Net-Current-Asset-Value | 2.39 | |||||
| Price-to-Net-Cash | 3.05 | |||||
| Earnings Yield (Greenblatt) % | -56.18 | |||||
| FCF Yield % | -38.53 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:UNCY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Unicycive Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.675 | ||
| EPS (TTM) ($) | -0.97 | ||
| Beta | 2.47 | ||
| Volatility % | 116.01 | ||
| 14-Day RSI | 51.41 | ||
| 14-Day ATR ($) | 0.069676 | ||
| 20-Day SMA ($) | 0.699625 | ||
| 12-1 Month Momentum % | -8.62 | ||
| 52-Week Range ($) | 0.202 - 1.818 | ||
| Shares Outstanding (Mil) | 103.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Unicycive Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Unicycive Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Unicycive Therapeutics Inc Frequently Asked Questions
What is Unicycive Therapeutics Inc(UNCY)'s stock price today?
The current price of UNCY is $0.67. The 52 week high of UNCY is $1.82 and 52 week low is $0.20.
When is next earnings date of Unicycive Therapeutics Inc(UNCY)?
The next earnings date of Unicycive Therapeutics Inc(UNCY) is 2025-03-28 Est..
Does Unicycive Therapeutics Inc(UNCY) pay dividends? If so, how much?
Unicycive Therapeutics Inc(UNCY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers